Stada and Barr are out of the running for Merck KGaA's generic unit, following the first round of bidding, the Economic Times reported citing sources close to the company.
Ranbaxy, Teva, Mylan and are among the shortlisted companies, the newspaper said.
No comments:
Post a Comment